Targeting PARP enzymes—While PARP inhibition is a therapeutic option in an increasing number of cancer histotypes [138], the “repurposing” of PARP inhibitors in the context of COVID-19 infection, with the aim of tapering overzealous immune responses and their potentially detrimental effects, has been hypothesized, but has not yet been tested in the clinic [198]. This evidence concerns the gene PARP1 and cancer.